Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities

Jeong, Sehan; Afroz, Sharmin; Kang, Donghyun; Noh, Jeonghwan; Suh, Jooyeon; Kim, June Hyuk; You, Hye Jin; Kang, Hyun Guy; Kim, Yi-Jun; Kim, Jin-Hong

doi:10.14348/molcells.2023.0079

Cited by 1 publication

(1 citation statement)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although Immunotherapy has revolutionized cancer treatment, immuno‐oncology agents have not yet been approved for patients with sarcomas attributed to the limitations of low tumor mutation burden and the immunosuppressive TME [ 115 ]. However, several research have indicated that immunotherapy may represent an efficient therapeutic strategy for this group of diseases, including cancer vaccines, immune checkpoint blockade and adoptive cell transfer [ 116 ]. Future studies investigating novel immunotherapy strategies in rare cancer types like sarcomas should incorporate the analysis and intervention of commensal bacteria, which will allow for a better understanding of the gut microbiota involved in sensitivity and treatment resistance to immune‐oncology agents.…”

Section: Discussionmentioning

confidence: 99%

Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies

Xie,

Liu,

Deng

et al. 2024

iMeta

View full text Add to dashboard Cite

Gut microbiota is essential for maintaining local and systemic immune homeostasis in the presence of bacterial challenges. It has been demonstrated that microbiota play contrasting roles in cancer development as well as anticancer immunity. Cancer immunotherapy, a novel anticancer therapy that relies on the stimulation of host immunity, has suffered from a low responding rate and incidence of severe immune‐related adverse events (irAEs). Previous studies have demonstrated that the diversity and composition of gut microbiota were associated with the heterogeneity of therapeutic effects. Therefore, alteration in microbiota taxa can lead to improved clinical outcomes in immunotherapy. In this review, we determine whether microbiota composition or microbiota‐derived metabolites are linked to responses to immunotherapy and irAEs. Moreover, we discuss various approaches to improve immunotherapy efficacy or reduce toxicities by modulating microbiota composition.

show abstract

Section: Discussionmentioning

confidence: 99%